Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

Rhea-AI Summary

Agios Pharmaceuticals (NASDAQ: AGIO) is set to present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 10:30 a.m. ET. The presentation will focus on Agios's pioneering work in therapies for genetically defined diseases and its leadership in cellular metabolism. A live webcast can be accessed via their website, with an archived replay available for two weeks. Agios develops treatments for conditions like pyruvate kinase deficiency, with a strong clinical pipeline addressing thalassemia, sickle cell disease, and more.

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 10:30 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at www.agios.com.

Contacts

Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
Holly.Manning@agios.com

Media:
Jessica Rennekamp, 857-209-3286
Director, Corporate Communications
Jessica.Rennekamp@agios.com 

FAQ

When will Agios Pharmaceuticals present at the RBC Capital Markets Global Healthcare Conference?

Agios Pharmaceuticals will present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 10:30 a.m. ET.

How can I watch the Agios Pharmaceuticals presentation live?

The live webcast of the Agios Pharmaceuticals presentation can be accessed on their website under 'Events & Presentations' in the Investors section.

What is the focus of Agios Pharmaceuticals' presentation at the conference?

The presentation will highlight Agios's advancements in therapies for genetically defined diseases and their leadership in cellular metabolism.

Will there be a replay of the Agios Pharmaceuticals presentation available?

Yes, a replay of the Agios Pharmaceuticals presentation will be archived on their website for at least two weeks after the event.

What is the primary therapy marketed by Agios Pharmaceuticals?

Agios Pharmaceuticals markets a first-in-class pyruvate kinase activator for adults with PK deficiency, a serious hemolytic anemia.